The Biosimilars Operational Readiness group is an initiative focused on developing resources to aid in the assessment and implementation of biosimilars when formulary coverage is approved. This group will launch in Q4 2022.
Breast cancer is the most common cancer diagnosed in the US, and it is also the most common cancer diagnosed worldwide. In the US alone, approximately 4 million women are diagnosed with the disease.
Partnership Forum: This forum helped identify payer needs and current barriers that payer currently face regarding evidence for therapies approved through an expedited approval process. In addition, participants identified potential solutions to address evidence gaps.
November 2022 Legislative & Regulatory Briefing; The PIE Act of 2022 Reintroduced with Bipartisan Support; Member Benefit! Catch Up on the Latest Regulatory NewsBREAKs; CMS Hiring for IRA Implementation; AMCP's Jennifer Mathieu Selected as a Top 20 in 2022 by The Advocacy Association; AMCP Makes Its Voice Heard, Submits Comments on Simplified Enrollment for Medicaid, CHIP, and Basic Health Programs; Now Open: Nominate an Individual for AMCP's Advocate of the Year Award.
